Raphaël Genolet

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


28 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2014 | 2013 | 2012 | 2010 | 2005 | 2004 |
2024
 
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy.
Ghasemi A., Martinez-Usatorre A., Li L., Hicham M., Guichard A., Marcone R., Fournier N., Torchia B., Martinez Bedoya D., Davanture S. et al., 2024/02. Nature cancer, 5 (2) pp. 240-261. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4DE2DD03AF35]
2023
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
Fallet B., Foglierini M., Porret R., Alcaraz-Serna A., Sauvage C., Jenelten R., Caplanusi T., Gilliet M., Perez L., Fenwick C. et al., 2023/08. The Journal of infection, 87 (2) pp. 111-119. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9DA429039D3E]
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
Racle J., Guillaume P., Schmidt J., Michaux J., Larabi A., Lau K., Perez MAS, Croce G., Genolet R., Coukos G. et al., 2023/06/13. Immunity, 56 (6) pp. 1359-1375.e13. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9BA5A00EAA19]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R., Bobisse S., Chiffelle J., Arnaud M., Petremand R., Queiroz L., Michel A., Reichenbach P., Cesbron J., Auger A. et al., 2023/04/24. Cell reports methods, 3 (4) p. 100459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC23FF064822]
Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8(+ )T-cell epitopes.
Gfeller D., Schmidt J., Croce G., Guillaume P., Bobisse S., Genolet R., Queiroz L., Cesbron J., Racle J., Harari A., 2023/01/18. Cell systems, 14 (1) pp. 72-83.e5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_53359DC7F7C1]
2022
 
A new workflow combining magnetic cell separation and impedance-based cell dispensing for gentle, simple and reliable cloning of specific CD8+ T cells.
Ben Khelil M., Aeberli L., Perchaud M., Genolet R., Abdeljaoued S., Borg C., Binda D., Harari A., Jandus C., Muller G. et al., 2022/04. SLAS technology, 27 (2) pp. 130-134. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_97892CDB341E]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
2021
 
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J., Turrini R., Minasyan A., Barras D., Crespo I., Grimm A.J., Casado J., Genolet R., Benedetti F., Wicky A. et al., 2021/12/13. Cancer cell, 39 (12) pp. 1623-1642.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4A546D8AF05A]
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745449157CA6]
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
Cachot A., Bilous M., Liu Y.C., Li X., Saillard M., Cenerenti M., Rockinger G.A., Wyss T., Guillaume P., Schmidt J. et al., 2021/02. Science advances, 7 (9) pp. eabe3348. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7FDE10B2A046]
2020
 
Disturbed mitochondrial dynamics in CD8<sup>+</sup> TILs reinforce T cell exhaustion.
Yu Y.R., Imrichova H., Wang H., Chao T., Xiao Z., Gao M., Rincon-Restrepo M., Franco F., Genolet R., Cheng W.C. et al., 2020/12. Nature immunology, 21 (12) pp. 1540-1551. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_89908ED24FA7]
T-cell repertoire analysis and metrics of diversity and clonality.
Chiffelle J., Genolet R., Perez M.A., Coukos G., Zoete V., Harari A., 2020/10. Current opinion in biotechnology, 65 pp. 284-295. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_598F3EDCA20B]
2019
 
High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
Costa-Nunes C., Cachot A., Bobisse S., Arnaud M., Genolet R., Baumgaertner P., Speiser D.E., Sousa Alves P.M., Sandoval F., Adotévi O. et al., 2019/07/15. Clinical cancer research, 25 (14) pp. 4320-4331. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_99ED3D648751]
2018
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBC10D090AEF]
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10AE95ADCEE8]
2017
 
Label-free identification of activated T lymphocytes through tridimensional microsensors on chip.
Rollo E., Tenaglia E., Genolet R., Bianchi E., Harari A., Coukos G., Guiducci C., 2017/08/15. Biosensors & bioelectronics, 94 pp. 193-199. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8DDCB6B9A58E]
2014
 
Duality of the murine CD8 compartment.
Genolet R., Leignadier J., Osterås M., Farinelli L., Stevenson B.J., Luescher I.F., 2014. Proceedings of the National Academy of Sciences of the United States of America, 111 (11) pp. E1007-E1015.
[DOI][WoS][Pmid][serval:BIB_44A5E373034A]
2013
 
CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire.
Verhagen J., Genolet R., Britton G.J., Stevenson B.J., Sabatos-Peyton C.A., Dyson J., Luescher I.F., Wraith D.C., 2013. Proceedings of the National Academy of Sciences of the United States of America, 110 (3) pp. E221-E230. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C32A40C6995C]
2012
 
Highly diverse TCRα chain repertoire of pre-immune CD8(+) T cells reveals new insights in gene recombination.
Genolet R., Stevenson B.J., Farinelli L., Osterås M., Luescher I.F., 2012. Embo Journal, 31 (7) pp. 1666-1678. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2B947DF61C00]
 
KAP1 regulates gene networks controlling T-cell development and responsiveness.
Santoni de Sio F.R., Barde I., Offner S., Kapopoulou A., Corsinotti A., Bojkowska K., Genolet R., Thomas J.H., Luescher I.F., Pinschewer D. et al., 2012. FASEB Journal, 26 (11) pp. 4561-4575.
[DOI][WoS][Pmid][serval:BIB_84EB5469EE09]
 
The T-cell receptor is not hardwired to engage MHC ligands.
Holland S.J., Bartok I., Attaf M., Genolet R., Luescher I.F., Kotsiou E., Richard A., Wang E., White M., Coe D.J. et al., 2012. Proceedings of the National Academy of Sciences of the United States of America, 109 (45) pp. E3111-E3118. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F0C56D069094]
2010
 
Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A., Genolet R., Legler D.F., Luther S.A., Luescher I.F., 2010. Journal of Immunology, 185 (6) pp. 3445-3455. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FF2FB8BC9031]
2005
 
Peroxisome proliferator activated receptors
Genolet R., Michalik L., Wahli W., 2005. pp. 267-280 dans Dufour J.F., Clavien P.A., Trautwein C., Graf R. (eds.) Signaling pathways in liver diseases, Springer.
[serval:BIB_4496A38F14EF]
 
Promoter rearrangements cause species-specific hepatic regulation of the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor alpha.
Genolet R., Kersten S., Braissant O., Mandard S., Tan N.S., Bucher P., Desvergne B., Michalik L., Wahli W., 2005. Journal of Biological Chemistry, 280 (25) pp. 24143-24152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_038A574254CF]
2004
 
PPARs as drug targets to modulate inflammatory responses?
Genolet R., Wahli W., Michalik L., 2004. Current Drug Targets. Inflammation and Allergy, 3 (4) pp. 361-375. Peer-reviewed.
[Pmid][serval:BIB_31EA877D4824]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University